Suppr超能文献

凝血因子Xa在决定全血凝块促凝活性中的重要性。

Importance of factor Xa in determining the procoagulant activity of whole-blood clots.

作者信息

Eisenberg P R, Siegel J E, Abendschein D R, Miletich J P

机构信息

Cardiovascular Division, Washington University School of Medicine, St. Louis, Missouri 63110.

出版信息

J Clin Invest. 1993 May;91(5):1877-83. doi: 10.1172/JCI116404.

Abstract

The binding of thrombin to fibrin is thought to be an important mechanism by which thrombi exhibit procoagulant activity; however, the extent to which other procoagulants are associated with thrombi has not been previously defined. This study was designed to determine whether clotting factors other than thrombin are bound to whole-blood clots and can thereby contribute to significant procoagulant activity. Clots formed in vitro from human blood exhibited minimal thrombin activity when incubated in plasma depleted of vitamin K-dependent factors by barium-citrate adsorption, as indicated by increases in the concentration of fibrinopeptide A (FPA), a marker of fibrin formation, to 72 nM after 30 min. Incubation of clots in barium-absorbed plasma repleted with 0.9 microM human prothrombin under the same conditions resulted in marked increases in the concentration of FPA (> 1,000 nM) and clotting by 30 min. The increases in FPA were attributable to activation of the added prothrombin by clot-associated Factor Xa, judging from concomitant increases in the concentration of prothrombin fragment 1.2. Similar results were obtained with thrombi induced in the axillary arteries of dogs by vascular injury and incubated with plasma in vitro. Activation of prothrombin was inhibited in a dose-dependent manner by tick anticoagulant peptide, a direct inhibitor of Factor Xa, at concentrations of 0.5-5.0 microM. Clot-associated Factor Xa activity was resistant to inhibition by anti-thrombin III, judging from the lack of inhibition of prothrombin activation during incubation of clots in plasma containing heparin pentasaccharide, an anti-thrombin III-mediated inhibitor of Factor Xa. Thus, the activity of Factor Xa appears to be an important determinant of the procoagulant activity of whole-blood clots and arterial thrombi, and is resistant to inhibition by anti-thrombin III-dependent inhibitors.

摘要

凝血酶与纤维蛋白的结合被认为是血栓表现出促凝活性的一个重要机制;然而,此前尚未明确其他促凝剂与血栓相关的程度。本研究旨在确定除凝血酶外的凝血因子是否与全血凝块结合,从而导致显著的促凝活性。通过钡-柠檬酸盐吸附使血浆中维生素K依赖因子耗尽后,用人血在体外形成的凝块在孵育时显示出最小的凝血酶活性,纤维蛋白形成标志物纤维蛋白肽A(FPA)的浓度在30分钟后增加到72 nM即可表明这一点。在相同条件下,将凝块在补充有0.9 microM人凝血酶原的钡吸收血浆中孵育,导致FPA浓度显著增加(>1000 nM),并在30分钟内出现凝血。从凝血酶原片段1.2浓度的同时增加判断,FPA的增加归因于凝块相关的因子Xa对添加的凝血酶原的激活。用血管损伤诱导犬腋动脉血栓并在体外与血浆孵育也得到了类似结果。蜱抗凝肽是因子Xa的直接抑制剂,在浓度为0.5 - 5.0 microM时以剂量依赖方式抑制凝血酶原的激活。从在含有肝素五糖(一种抗凝血酶III介导的因子Xa抑制剂)的血浆中孵育凝块期间凝血酶原激活未受抑制来看,凝块相关的因子Xa活性对抗凝血酶III的抑制具有抗性。因此,因子Xa的活性似乎是全血凝块和动脉血栓促凝活性的一个重要决定因素,并且对抗凝血酶III依赖性抑制剂具有抗性。

相似文献

4
Prolonged activation of prothrombin on the vascular wall after arterial injury.
Arterioscler Thromb Vasc Biol. 1998 Feb;18(2):250-7. doi: 10.1161/01.atv.18.2.250.

引用本文的文献

3
Laboratory assessment of rivaroxaban: a review.利伐沙班的实验室评估:综述。
Thromb J. 2013 Jul 3;11(1):11. doi: 10.1186/1477-9560-11-11.
4
Oral anticoagulants in older adults with atrial fibrillation.老年房颤患者的口服抗凝剂
J Thromb Thrombolysis. 2013 Nov;36(4):403-15. doi: 10.1007/s11239-013-0869-0.
5
Rivaroxaban delivery and reversal at a venous flow rate.利伐沙班在静脉血流速率下的输送和逆转。
Arterioscler Thromb Vasc Biol. 2012 Dec;32(12):2877-83. doi: 10.1161/ATVBAHA.112.300053. Epub 2012 Sep 27.

本文引用的文献

7
Measurement of fibrinopeptide A in human blood.人体血液中纤维蛋白肽A的测定。
J Clin Invest. 1974 Jul;54(1):43-53. doi: 10.1172/JCI107749.
8
Fibrinopeptide A: a marker of acute coronary thrombosis.
Circulation. 1985 May;71(5):912-8. doi: 10.1161/01.cir.71.5.912.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验